Epistaxis in end stage liver disease masquerading as severe upper gastrointestinal hemorrhage

AIM:To describe the prevalence,diagnosis,treatment,and outcomes of end stage liver disease(ESLD) patients with severe epistaxis thought to be severe upper gastrointestinal hemorrhage(UGIH).METHODS:This observational single center study included all consecutive patients with ESLD and epistaxis identi...

Full description

Saved in:
Bibliographic Details
Published in:World journal of gastroenterology : WJG Vol. 20; no. 38; pp. 13993 - 13998
Main Authors: Camus, Marine, Jensen, Dennis M, Matthews, Jason D, Ohning, Gordon V, Kovacs, Thomas O, Jutabha, Rome, Ghassemi, Kevin A, Machicado, Gustavo A, Dulai, Gareth S
Format: Journal Article
Language:English
Published: United States Baishideng Publishing Group Inc 14-10-2014
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:AIM:To describe the prevalence,diagnosis,treatment,and outcomes of end stage liver disease(ESLD) patients with severe epistaxis thought to be severe upper gastrointestinal hemorrhage(UGIH).METHODS:This observational single center study included all consecutive patients with ESLD and epistaxis identified from consecutive subjects hospitalized with suspected UGIH and prospectively enrolled in our databases of severe UGIH between 1998 and 2011.RESULTS:A total of 1249 patients were registered for severe UGIH in the data basis,461(36.9%) were cirrhotics. Epistaxis rather than UGIH was the bleeding source in 20 patients. All patients had severe coagulopathy. Epistaxis was initially controlled in all cases. Fifteen(75%) subjects required posterior nasal packing and 2(10%) embolization in addition to correction of coagulopathy. Five(25%) patients died in the hospital,12(60%) received orthotopic liver transplantation(OLT),and 3(15%) were discharged without OLT. The mortality rate was 63% in patients without OLT.CONCLUSION:Severe epistaxis in patients with ESLD is(1) a diagnosis of exclusion that requires upper endoscopy to exclude severe UGIH;and(2) associated with a high mortality rate in patients not receiving OLT.
Bibliography:Marine Camus;Dennis M Jensen;Jason D Matthews;Gordon V Ohning;Thomas O Kovacs;Rome Jutabha;Kevin A Ghassemi;Gustavo A Machicado;Gareth S Dulai;CURE Hemostasis Research Group,CURE Digestive Diseases Research Center,David Geffen School of Medicine at University of California;Division of Digestive Diseases at University of California,Los Angeles,Ronald Reagan Medical Center;Department of Gastroenterology,Lariboisiere Hospital;CURE Hemostasis Research Group,CURE Digestive Diseases Research Center,David Geffen School of Medicine at University of California,Los Angeles,Los Angeles,CA 90095,United States;Gastroenterology Division at VA Greater Los Angeles Healthcare System;Hunterdon Gastrointestinal Associates
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Undefined-2
Telephone: +33-6-81933140 Fax: +33-1-49952577
Correspondence to: Marine Camus, MD, Assistant Professor, Department of Gastroenterology, Lariboisiere Hospital, APHP, 2 rue Ambroise Pare, 75010 Paris, France. marine.camus@gmail.com
Author contributions: Jensen DM and Matthews JD designed research; Ohning GV, Kovacs TO, Jutabha R, Ghassemi KA, Machicado GA and Dulai GS performed research; Camus M contributed new reagents/analytic tools; Camus M and Jensen DM analyzed data; Camus M, Matthews JD and Jensen DM wrote the paper.
ISSN:1007-9327
2219-2840
DOI:10.3748/wjg.v20.i38.13993